{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:22:36Z","timestamp":1781950956725,"version":"3.54.5"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.neurol.2007.09.005","type":"journal-article","created":{"date-parts":[[2008,3,3]],"date-time":"2008-03-03T15:15:48Z","timestamp":1204557348000},"page":"278-279","source":"Crossref","is-referenced-by-count":8,"title":["Hypertension art\u00e9rielle pulmonaire isol\u00e9e et pergolide"],"prefix":"10.1016","volume":"164","author":[{"given":"F.","family":"Evrard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jacquerye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2007.09.005_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2007.09.005_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","article-title":"Pergolide use in Parkinson disease is associated with cardiac valve regurgitation","volume":"63","author":"Baseman","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.09.005_bib3","first-page":"111","article-title":"Imputabilit\u00e9 des effets inattendus ou toxiques des m\u00e9dicaments. Actualisation de la m\u00e9thode utilis\u00e9e en France","volume":"40","author":"Begaud","year":"1985","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.neurol.2007.09.005_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0035-3787(04)70850-4","article-title":"Valvulopathie r\u00e9versible et traitement par pergolide","volume":"160","author":"Calomne","year":"2004","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2007.09.005_bib5","first-page":"101","article-title":"Pergolide associated valvulopathies: 11 cases observed in Belgium. Program and abstracts of the 57th Annual Meeting of the American Academy of Neurology; April 9-16; Miami Beach, Florida","author":"Evrard","year":"2005","journal-title":"Poster Presentation P02"},{"key":"10.1016\/j.neurol.2007.09.005_bib6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4065\/74.12.1191","article-title":"Echographic improvement over time after cessation of use of fenfluramine and phentermine","volume":"74","author":"Hensrud","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.neurol.2007.09.005_bib7","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5HT-2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.neurol.2007.09.005_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide","volume":"61","author":"Van Camp","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.09.005_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378708000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378708000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T04:51:50Z","timestamp":1546231910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378708000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0035378708000404"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2007.09.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}